92042-93-8

Basic information

• Product Name: (4-BENZYLPIPERAZIN-1-YL)ACETONITRILE
• Synonyms: 1-(CYANOMEHTYL)-4-BENZYLPIPERAZINE;4-Benzylpiperazine-1-acetonitrile
• CAS NO: 92042-93-8
• Molecular Formula: C₁₃H₁₇N₃
• Molecular Weight: 215.29
• Mol File: 92042-93-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 345.7°C at 760 mmHg
• Flash Point: 146.5°C
• Appearance: /
• Density: 1.088g/cm³
• Vapor Pressure: 6.05E-05mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: (4-BENZYLPIPERAZIN-1-YL)ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-BENZYLPIPERAZIN-1-YL)ACETONITRILE(92042-93-8)
• EPA Substance Registry System: (4-BENZYLPIPERAZIN-1-YL)ACETONITRILE(92042-93-8)

Safety Data

• Hazardous Substances Data: 92042-93-8(Hazardous Substances Data)

Usage

General Description

(4-Benzylpiperazin-1-yl)acetonitrile is a chemical compound that contains a piperazine ring and a benzyl group attached to it. It is classified as an acetonitrile derivative and is used in the pharmaceutical industry as a building block for the synthesis of various drugs and bioactive compounds. The presence of the piperazine ring and the benzyl group makes it a potential candidate for the development of new therapeutic agents, particularly in the field of central nervous system disorders. Its molecular structure and properties make it a valuable intermediate in the preparation of diverse organic compounds with potential pharmacological activities.

InChI:InChI=1/C13H17N3/c14-6-7-15-8-10-16(11-9-15)12-13-4-2-1-3-5-13/h1-5H,7-12H2

Upstream product

• 2759-28-6 1-phenylmethylpiperazine 
• 107-14-2 chloroacetonitrile 
• 590-17-0 cyanomethyl bromide 
• 83991-49-5 1-[(4-benzylpiperazin-1-yl)methyl]-1H-benzo[d][1,2,3]triazole 
• 143-33-9 sodium cyanide 
• 110475-31-5 N-benzyl-piperazine hydrochloride 
• 50-00-0 formaldehyd 

Downstream Products

• 4553-21-3 2-(4-benzylpiperazin-1-yl)-ethylamine 
• 847573-77-7 4-[[2-(4-benzylpiperazin-1-yl)ethyl]amino]-6,7-methylenedioxyquinoline 
• 847573-93-7 8,9-dimethoxy-2,3-methylenedioxy-5-[2-(4-benzylpiperazin-1-yl)ethyl]-5H-dibenzo[c,h]1,6-naphthyridin-6-one 
• 847573-85-7 N-(6,7-methylenedioxyquinolin-4-yl)-N-[2-(4-benzylpiperazin-1-yl)ethyl]-2-iodo-4,5-dimethoxybenzamide 
• 187221-43-8 4-Fluoro-N-(2-piperazin-1-yl-ethyl)-benzamide 
• 159671-82-6 N-(2-(4-Benzylpiperazin-1-yl)ethyl)-4-fluorobenzamide 
• 100221-93-0 N-[2-(4-Benzyl-piperazin-1-yl)-ethyl]-2-methyl-benzamide 
• 100221-94-1 N-(2-(4-Benzylpiperazin-1-yl)ethyl)benzamide 
• 100221-91-8 N-(2-(4-Benzylpiperazin-1-yl)ethyl)-2-chlorobenzamide 
• 100221-90-7 N-[2-(4-Benzyl-piperazin-1-yl)-ethyl]-2-bromo-benzamide 
• 100221-89-4 N-[2-(4-Benzyl-piperazin-1-yl)-ethyl]-2-iodo-benzamide 
• 100221-92-9 N-(2-(4-Benzylpiperazin-1-yl)ethyl)-2-nitrobenzamide 
• 1007869-45-5 N-[2-[4-(phenylmethyl)piperazinyl]ethyl]carbamic acid 1,1-dimethylethyl ester 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

Provided herein are compounds, such as compounds for use in treating cancer. Also provided are methods of treating cancer, including treatment resistant cancer or cancer associated with a hypoxic tumor.

Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease

Development of Multi-Target Directed Ligands (MTDLs) has emerged as a promising approach for targeting complex etiology of Alzheimer's disease (AD). Following this approach, a new series of N′-(4-benzylpiperidin-/piperazin-/benzhydrylpiperazin-1-yl)alkylamine derivatives were designed, synthesized and biologically evaluated as inhibitors of cholinesterases (ChEs), amyloid-beta (Aβ) self aggregation and also for their radical scavenging activity. The in vitro studies showed that the majority of synthesized derivatives strongly inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values in the low-nanomolar range, and were clearly more potent than the reference compound donepezil in this regard. Among them, inhibitors 5h and 5k, strongly inhibited AChE, with IC50 value of 6.83 nM and 2.13 nM, respectively, and particularly, compound 5k was found to be highly selective for AChE (～38-fold). Moreover, both kinetic analysis of AChE inhibition and the docking study suggested that 5k binds simultaneously to catalytic active site and peripheral anionic site of AChE. Besides, these compounds also exhibited greater ability to inhibit self-induced Aβ1-42 aggregation at 25 μM with percentage inhibition from ～54% to 89% and specially compound 5k provided highest inhibition (88.81%). Also, the derivatives containing methoxy and hydroxy groups showed potent oxygen radical absorbance capacity (ORAC) ranging from 2.2- to 4.4-fold of the Trolox value. Furthermore, results of ADMET studies suggested that all compounds exhibited appropriate drug like properties. Taken together, these results suggest that 5k might be a promising lead compound for further AD drug development.

Synthesis, characterization and in vitro biological studies of novel cyano derivatives of N-alkyl and N-aryl piperazine

Cyano derivatives of N-alkyl and N-aryl piperazine have been synthesized and screened for antibacterial and antifungal activities. All the synthesized compounds showed the antibacterial activity against pathogenic strains of Staphylococcus aureus (MTCCB 737), Pseudomonas aeruginosa (MTCCB 741), Streptomyces epidermidis (MTCCB 1824) and Escherichia coli (MTCCB 1652) and antifungal activity against pathogenic strains of Aspergillus fumigatus (ITCC 4517), Aspergillus flavus (ITCC 5192) and Aspergillus niger (ITCC 5405). All compounds showed mild to moderate antimicrobial activity. However, compounds 3c, 4a and 6 showed potent antibacterial activity against pathogenic strains used in the study. Compounds 3a, 3b, 4b, and 4d showed mild to moderate antifungal activity against Aspergillus pathogenic strains. The compounds reported in this study were assessed for there cytotoxicity using MTT colorimetric assay on Hela cells. All the compounds showed cell viability more than the control drug gentamicin, with compound 2 having highest i.e. 95% cell viability.